- active not recruitingPHASE3
A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5)
This study is testing a new medication called donanemab for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow memory and thinking problems. It's a key step in understanding potential new treatments for this condition.
Argentina · Australia · China - recruitingNA
Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity
This study looks at how increasing physical activity might help slow down memory and thinking problems in people with a condition called REM sleep behaviour disorder (iRBD). This condition can sometimes lead to Parkinson's disease. Participants will use a smartphone app to boost their activity levels.
Germany - recruitingPHASE1, PHASE2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
This study looks at new drug combinations (Elacestrant and Abemaciclib) for people with breast cancer that has spread to the brain. It aims to find the right dose and see how well the new combination works for ER-positive, HER-2 negative breast cancer.
United States · Belgium · France - recruitingNA
Treating Depression on a Day-to-day Basis: Development of a Tool for Physicians Based on a Smartphone Application
This study is checking if a smartphone app can help doctors better understand and treat depression. It aims to improve how doctors provide care by looking at daily symptoms and how well people take their medication, using a mobile phone tool to gather information.
France - not yet recruiting
Longitudinal Assessment of Protein Markers in the Cerebrospinal Fluid of Patients With Central Nervous System Involvement
This study looks for clues in spinal fluid from children with brain and nerve conditions. We're hoping to find patterns that could help doctors diagnose these conditions earlier and more accurately in the future. It's about making future tests better for children.
France - active not recruitingPHASE3
A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)
This study is looking at different ways of giving a medicine called donanemab for early Alzheimer's disease. Researchers want to see how different doses affect side effects and which patients might be more likely to experience them. It's for adults aged 60-85.
United States · United Kingdom